Anzeige
Mehr »
Login
Mittwoch, 30.11.2022 Börsentäglich über 12.000 News von 680 internationalen Medien
Keine Hexerei! Multi-1.000-Prozenter mit Ansage?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0EAT9 ISIN: BE0003818359 Ticker-Symbol: GXE 
Tradegate
30.11.22
19:46 Uhr
37,990 Euro
+0,170
+0,45 %
Branche
Biotechnologie
Aktienmarkt
BEL-20
AMX
1-Jahres-Chart
GALAPAGOS NV Chart 1 Jahr
5-Tage-Chart
GALAPAGOS NV 5-Tage-Chart
RealtimeGeldBriefZeit
38,10038,49020:53
38,24038,41020:53

Aktuelle News zur GALAPAGOS NV Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.11.Hedge Fund and Insider Trading News: Christopher Hohn, Davidson Kempner Capital Management, Tiger Global Management, Galapagos Capital, Highpeak Energy Inc (HPK), HireRight Holdings Corporation (HRT), and More9
10.11.Galapagos NV: Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca following extensive safety review of all JAK inhibitors365Supportive outcome for Jyseleca as treatment option with a positive benefit/risk profile after review of safety data of all JAK inhibitors approved in Europe for treatment of inflammatory conditions...
► Artikel lesen
08.11.Galapagos NV: Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022442Preliminary results from real-world FILOSOPHY, FILgotinib Observational Study Of Patient Health-related outcomes, in the first 200 patients with moderately to severely active rheumatoid arthritis (RA)Data...
► Artikel lesen
07.11.Where Galapagos Stands With Analysts13
07.11.Galapagos downgraded to market perform at Raymond James on unclear path forward12
GALAPAGOS NV Aktie jetzt für 0€ handeln
04.11.GALAPAGOS NV - 6-K, Report of foreign issuer5
04.11.Galapagos NV: Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022511Guiding principles for a sustainable future: Invest in strategic therapeutic areas of oncology and immunologyRebuild and accelerate portfolio of transformational medicines in high unmet...
► Artikel lesen
04.11.Galapagos lays off 200 staff, drops kidney and fibrosis programs in renewed CAR-T push19
04.11.Galapagos' new CEO Paul Stoffels wields axe in bid to go 'forward, faster'16
03.11.'Forward, faster' and 200 jobs lighter as fibrosis and kidney disease get cut, Galapagos CEO Stoffels once again spotlights deals10
03.11.Galapagos NV: Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results432Clear path forward for accelerated growth and value creation Reshape innovation model and build fit-for-purpose organization in key strategic therapeutic areas: immunology and oncologyJyseleca 2022...
► Artikel lesen
21.10.XETR DELETION OF INSTRUMENTS FROM XETRA - 21.10.2022 - 12.228The following instruments on Xetra do have their last trading day on 21.10.2022Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 21.10.2022ISIN NameDK0010244425 A.P.Moeller-Maersk...
► Artikel lesen
17.10.GALAPAGOS NV - 6-K, Report of foreign issuer2
17.10.Galapagos NV: Galapagos to host its R&D Update 2022 in New York on 4 November 2022296Mechelen, Belgium; 17 October 2022, 07.30 CET; - Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host its R&D Day 2022 for analysts, investors and financial press...
► Artikel lesen
06.10.GALAPAGOS NV - 6-K, Report of foreign issuer4
06.10.Galapagos NV: Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress436Five presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityNew analyses will be presented from the SELECTION data set on prediction of response and...
► Artikel lesen
04.10.Sabine Koken wird Geschäftsführerin bei Galapagos Biopharma4
04.10.EQS-News: Galapagos Biopharma Deutschland GmbH: Dr. Sabine Koken geht als neue Steuerfrau bei Galapagos Biopharma Deutschland an Bord401EQS-News: Galapagos Biopharma Deutschland GmbH / Schlagwort(e): Personalie Dr. Sabine Koken geht als neue Steuerfrau bei Galapagos Biopharma Deutschland an Bord 04.10.2022 / 10:00...
► Artikel lesen
03.10.EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects-
03.10.Galapagos NV: Galapagos receives positive CHMP opinion for Jyseleca European label update based on testicular function safety data from MANTA/RAy studies472Type II variation1 regulatory application to amend the European label of Jyseleca (filgotinib) based on data from MANTA and MANTA-RAy studies in patients with inflammatory bowel disease (IBD) and rheumatic...
► Artikel lesen
Seite:  Weiter >>
76 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1